Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Bicalutamide and Raloxifene in Prostate Cancer
NCT03147196Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Jun 2017
- Primary completion
- Jun 2022
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of raloxifene, bicalutamide in prostate adenocarcinoma, sponsored by Mayo Clinic. Planned start Jun 2017; status: withdrawn.
02
Drugs
raloxifenebicalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT03147196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03147196.